IRIDEX Corporation (IRIX) 12-Month Stock Forecast & Price Target Cone

$0.72 -2.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.71

IRIDEX Corporation (IRIX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRIX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, IRIDEX Corporation (NASDAQ: IRIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.72 (-2.92% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRIX ranks #909 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRIX compare to ITOC and NDRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), IRIX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 36.5%, and ROIC of -35.0%. By comparison, ITOC (iTonic Holdings Ltd (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M) and NDRA (ENDRA Life Sciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $7.3M). Among the 5-stock peer group, IRIX leads on earnings multiple (N/A) while IRIX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRIX?
▼

Per IRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0001006045), IRIDEX Corporation generated $52.7M in revenue (+8.2% YoY), -$4.4M in net income, and -$2.3M in free cash flow against $29.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.71 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (7)SEC (8)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.9% Base Target
$2 Bull$1 Base$0 Bear
📬 FREE IRIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRIX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY IRIX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$0.93-17.2% Next Q
Q2 (-2Q)
33
Grade E$0.77-2.6% Next Q
Q3 (-1Q)
31
Grade E$0.75-4% Next Q
Current
28
Grade E$0.72-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IRIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IRIX currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.72) and Max Pain ($0.76) forces dealer call-delta covering toward $1.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IRIX Beats Next Quarter EPS Consensus (Jan 2, 2027) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IRIX Position Size: $10,000

Shares at $0.72: 13888.9 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.48
$6,667
$-3,333 (-33.3%)
12M Consensus BaseTarget $0.62
$8,611
$-1,389 (-13.9%)
12M Bull Case BreakoutTarget $1.73
$24,028
+$14,028 (+140.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$269%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IRIX)

  • ✓Walkthrough of IRIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IRIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.94%▼ DESCENDING CHANNEL
2026-11-02O $0.74H $0.74L $0.72C $0.72VOL 26.4K
RES: $0.98SUP: $0.45SMA50: $0.72SMA200: $1.04
$1.24$1.07$0.90$0.73$0.56RES $0.98SUP $0.45$0.722026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IRIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRIX)

Health Care Rank #909 of 1016 ⚔️ ITOC vs IRIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRIX vs. ITOC, NDRA, QTI, POCI)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IRIDEX Corporation (IRIX) ranks #909 by composite RQD confidence (28/100, grade E) and #872 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, IRIX leads on earnings valuation at N/A trailing P/E, while IRIX leads on capital efficiency and profitability with -35.0% ROIC and 36.5% gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with IRIX at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IRIX ACTIVE
IRIDEX Corporation
E 28/100 — 36.5% -35.0% -2.92% $12.7M Benchmark Subject
ITOC
iTonic Holdings Ltd (Class A)
E 33/100 — 62.6% -35.0% -4.99% $20.9M /itoc-vs-irix →
NDRA
ENDRA Life Sciences Inc.
D- 42/100 — — -35.0% +2.95% $7.3M /ndra-vs-irix →
QTI
QT Imaging Holdings Inc.
E 29/100 — 45.4% -35.0% -3.07% $32.3M /qti-vs-irix →
POCI
Precision Optics Corporation Inc.
E 28/100 — 17.8% -35.0% +5.76% $50.5M /poci-vs-irix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-01-03 • CIK 0001006045

In its most recent audited fiscal period (FY2025, filed 2026-01-03), IRIDEX Corporation (IRIX) reported GAAP revenue of $52.7M (+8.2% vs. FY2024 revenue of $48.7M , and +1.6% cumulative change since FY2023) , GAAP net income of -$4.4M, operating cash flow of -$2.1M, and free cash flow of -$2.3M (+69.1% YoY). On the balance sheet, IRIX closed FY2025 with $29.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-01-03 $52.7M -$4.4M -$2.1M -$2.3M $29.2M —
FY2024 (FY) 2024-12-28 $48.7M -$8.9M -$7.3M -$7.3M $29.1M —
FY2023 (FY) 2023-12-30 $51.9M -$9.6M -$6.7M -$6.7M — —

3. IRIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, IRIDEX Corporation (NASDAQ: IRIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.72 (-2.92% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRIX ranks #909 in composite RQD confidence.

How does IRIX compare to ITOC and NDRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), IRIX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 36.5%, and ROIC of -35.0%. By comparison, ITOC (iTonic Holdings Ltd (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M) and NDRA (ENDRA Life Sciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $7.3M). Among the 5-stock peer group, IRIX leads on earnings multiple (N/A) while IRIX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IRIX?

Per IRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0001006045), IRIDEX Corporation generated $52.7M in revenue (+8.2% YoY), -$4.4M in net income, and -$2.3M in free cash flow against $29.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IRIX trading relative to its 50-day, 200-day, and 52-week technical levels?

IRIX last traded at $0.72 (-2.92% on volume of 26,381 shares), positioning the stock 0.00% above its 50-day simple moving average ($0.72) and -30.77% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.61 to $1.65, IRIX sits at the 10.6% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

IRIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IRIX's 12-month stock price target?

IRIDEX Corporation (IRIX) carries a 12-month consensus base price target of $0.62 (-13.9% from $0.72), with a bull-case target of $1.73 and a bear-case floor of $0.48.

Is IRIX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates IRIX E (Strong Sell — SELL) with an RQD Confidence score of 28/100.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%